The therapy combines low-dose IL-2 to expand T-reg numbers and function, with a CTLA-4 inhibitor to reduce surrounding inflammation. This dual approach addresses a key failure mode of prior T-reg therapies, where newly functional cells would quickly become dysfunctional again in the inflammatory disease environment.

Coya's treatment is a combination therapy that addresses two problems simultaneously. One component increases the number of functional regulatory T-cells (Tregs) to control the immune system. The second component suppresses the underlying inflammation that would otherwise cause these newly boosted cells to become dysfunctional again, ensuring a more durable effect.

Instead of targeting individual gene mutations in diseases like ALS, condensate science focuses on shared cellular structures where genetic risks converge. This approach creates a broader therapeutic target, potentially treating more patients with diverse genetic profiles.

Coya Therapeutics' vision is to make diseases like ALS "livable" by completely stopping their progression. This ambitious goal stems from a small investigator-initiated trial where patients showed no disease progression over six months, a period where a significant decline is typically expected, reframing the therapeutic benchmark.

Coya Therapeutics is pursuing a novel therapeutic goal for ALS: making the condition "livable" by stopping its progression. Instead of aiming for a cure or reversing existing damage, their strategy focuses on preserving a patient's current motor function, which would represent a significant breakthrough in managing the neurodegenerative disease.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

Diverging from typical approaches that focus on damaged neurons, Neuvivo's drug addresses ALS as an immune system disorder. By supplying a molecule the immune system is missing, it helps regulate the system, allowing the body to recover from the attacks that cause neurodegeneration.

After Novo Nordisk's GLP-1 trial in Alzheimer's failed to show clinical benefit despite a 10% biomarker improvement, Coya is pursuing a combination therapy. They theorize that adding low-dose IL-2 can synergistically boost biomarkers to the 25-30% range, a level they believe is necessary to achieve clinically meaningful effects.

Coya's therapeutic approach is not limited to ALS. The company views the underlying mechanism—dysfunctional regulatory T-cells driving neuroinflammation—as a common pathway in other conditions like frontotemporal dementia, Alzheimer's, and Parkinson's. This positions their drug as a platform technology, creating a broader pipeline and de-risking the company from reliance on a single indication.